MG-132

For research use only.

Catalog No.S2619

1171 publications

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Selleck's MG-132 has been cited by 1171 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.
Targets
Proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells M4TUTmZ2dmO2aX;uJGF{e2G7 NUHVN4d5OjVizszN M3XZdGROW09? M{PnfGlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszN MX6yOFY6PzR7Nh?=
HL-60 M1HkZ2N6fG:2b4jpZ{BCe3OjeR?= NW\BZ4xEPDBizszN NUDBVllTPDhiaB?= NI\s[2RFVVOR NHnvXW1KSzVyPEGwJO69VQ>? NVHJb4xmOjR4OUe0PVY>
SMMC-7721 MoPwR5l1d3SxeHnjJGF{e2G7 MXO0NEDPxE1? NYe3TXF[PDhiaB?= NVj3[HQ1TE2VTx?= M4f4XGlEPTB;Nz6xJO69VQ>? MUWyOFY6PzR7Nh?=
A-549 M33rS2N6fG:2b4jpZ{BCe3OjeR?= M{H0[|QxKM7:TR?= Mn7KOFghcA>? MUPEUXNQ M4OzeGlEPTB:MUCg{txO Mn3xNlQ3QTd2OU[=
MCF-7 Mlv5R5l1d3SxeHnjJGF{e2G7 NGS2RW01OCEQvF2= MWS0PEBp NVfsOZg3TE2VTx?= MnztTWM2OD15LkOg{txO MUCyOFY6PzR7Nh?=
SW-480 M1zheWN6fG:2b4jpZ{BCe3OjeR?= NIX3Uoc1OCEQvF2= NXi4bWpQPDhiaB?= NVr1bIRVTE2VTx?= M3W0TmlEPTB;NDFOwG0> M3vpe|I1Pjl5NEm2
NCI-H929 NGm1bGFEgXSxdH;4bYMhSXO|YYm= M3jGW|Eh|ryP NUG1PXZMPzJiaB?= NXr6PHI1TE2VTx?= M2njWWlEPTB;MD6xO{DPxE1? M2DhR|I1PjJ3MEi4
293T MUfDfZRwfG:6aXOgRZN{[Xl? MkHnNVAh|ryP Mn\FO|IhcA>? M2PBUWROW09? MU\JR|UxRDJizszN NXLxNFUzOjR4MkWwPFg>
293T NHnvZlRHfW6ldHnvckBCe3OjeR?= MVqxNEDPxE1? M{LCV|I1KGh? MoPISG1UVw>? MoDrUY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>? MnzONlQ3OjVyOEi=
HeLa M2XUUWtqdmG|ZTDBd5NigQ>? MoPtNVAh|ryP NYnVXVVUOSCq NWXjNlduTE2VTx?= NYrjS5RqUW6mdXPld{BRSVKSIHPs[YF3[WenIHL5JIlvcGmkaYTpcocheHKxc3Xhd49u\SCjY4Tpeol1gQ>? MWCyOFMzOTh|Mx?=
MDA-MB-231 M1HTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3pNUDPxE1? NWHWUWl5PzJiaB?= NGXpZZhFVVOR NXzR[Gh1UUN3ME2wMlE5KM7:TR?= M{PuZVI1OTV|MkC2
MCF-7 NEfXS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrmb4pjOSEQvF2= NHrUXYE4OiCq NUPi[|BTTE2VTx?= MlG2TWM2OD1yLkGzJO69VQ>? MYeyOFE2OzJyNh?=
MCF10A MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\sNUDPxE1? M3znR|czKGh? MX3EUXNQ Mn3DTWM2OD1yLkK5JO69VQ>? M4PMSlI1OTV|MkC2
HEK-293 NUHrTXg1U2mwYYPlJGF{e2G7 M2jjO|Ih[W6mIEKwJO69VQ>? MViyJIg> M3G5SmROW09? MVvJcohq[mm2czDDbHQuVCCjY4Tpeol1gSC5aYToJGlEPTBib3[gPUBvVSB? Mn3iNlM2PDB5OUC=
Calu6 NF7LS3RHfW6ldHnvckBCe3OjeR?= NFW3XJEyOCEQvF2= M1[yOVE5KGh? MlmxSG1UVw>? NWO2cldMW2mpbnnmbYNidnSueTDhZ4N2dXWuYYTld{BnemG2YYjpckBxemWldYLzc5I> NGPzNIgzOzVyNkS4Oi=>
IFN-gamma-induced RAW264.7 MVnGeY5kfGmxbjDBd5NigQ>? NYDme2p[TE2VTx?= MUfJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszN MXmyNlI4PzJ5Nx?=
IPC227F NXn1TYNCS3m2b4TvfIlkKEG|c3H5 MVixJO69VQ>? NIG2UHg1QCCq MYPEUXNQ NYTYVW1yUUN3ME2wMlA4PyEQvF2= MmTmNlE6OjR3Mki=
Hepa-1c1c7 M4XOV2Z2dmO2aX;uJGF{e2G7 MonNNlUh|ryP MY[2JIg> NWTRNYdSTE2VTx?= M370b2lv[3KnYYPld{BPemZ{IIDyc5RmcW5ibHX2[Yw> MljJNlA{QTJ3NES=
COS-7 NWW5OIhxS3m2b4TvfIlkKEG|c3H5 M3H1VVExKM7:TR?= MnjKSG1UVw>? NEnRfIVKSzVyPEGwJO69VQ>? Ml3UNVgxQDhyOUe=
HuH-7 NYrQWmJpS3m2b4TvfIlkKEG|c3H5 NITnfGQyOCEQvF2= NGXKZ4hFVVOR NF64UopKSzVyPEGwJO69VQ>? MUKxPFA5QDB7Nx?=
OCI-Ly3 MWDGeY5kfGmxbjDBd5NigQ>? M3zhOlExKM7:TdMg MV60JIg> NX\aOpNPTE2VTx?= MYXJcoR2[2W|IHj1cYFvKEmtYYDwZWJidHCqYTDzeIFjcWyrenH0bY9vKHerdHigSWM2OCCxZjCxJO69VQ>? NIPZc2MyQDB{NEGxNy=>
A2780 cDDP M2riOGFxd3C2b4Ppd{BCe3OjeR?= M2nIb|I1KGh? M2LBNGROW09? NYnGWmdNUW6mdXPld{BieG:ydH;zbZMh[nliaX7obYJqfGmwZzDQWGVPKGSnZ4Lh[IF1cW:w NYrYWVlJOTd4OESwNVg>
LPS-stimulated RAW264.7 cells NEDPT3ZHfW6ldHnvckBCe3OjeR?= MYfEUXNQ M{Do[WlvcGmkaYTzJG5HNWujcIDhRkBFVkFiYnnu[Ilv\w>? NI\0fVYyPzRyN{K3Oy=>
PC12 NVTtRVU4TnWwY4Tpc44hSXO|YYm= NVXHXYgyOTByIN88UeKh NGDxeWwzPCCq NIHCcYNFVVOR NGfTTGpKdmirYnn0d{A3NU:KRFGtJIFv\CCKMl:yMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MknMNVcyPTh2NUS=
PC3 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojCNlAh|ryP Mn\xOFghcA>? M4DMemROW09? Mn;nTWM2OD1yLk[g{txO MVGxOlY5PjV|Nx?=
LP-1 M2\lSmFxd3C2b4Ppd{BCe3OjeR?= M4fYblMxOCCwTR?= NIXv[ZkzPCCq NXK4OHVvTE2VTx?= M1:1VWlv\HWlZYOgZZBweHSxc3nzJIJ6KGmwY4LlZZNqdmdiY3zlZZZm\CCSQWLQJIxmfmWuIHHu[EBz\WS3Y3nu[{BO[2xvMTDwdo91\WmwIHzleoVt NGfONZkyPTl3OEW4PS=>
ES6 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEGzNFYh|ryP M3fQeHNCVkeHUh?=
A101D MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7YTI5IUUN3ME2wMlA{Ojd7IN88US=> M4PBV3NCVkeHUh?=
OCUB-M MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjGZo05UUN3ME2wMlA{PzN5IN88US=> MY\TRW5ITVJ?
LB2518-MEL M{nuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTGTWM2OD1yLkCzO|Yh|ryP MmTCV2FPT0WU
SH-4 NUTrUVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMESzNUDPxE1? M4LKW3NCVkeHUh?=
KNS-42 NFL2bZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPETWM2OD1yLkC0OFQyKM7:TR?= MlLsV2FPT0WU
DSH1 M3q2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLPVplYUUN3ME2wMlA2Ojh7IN88US=> NIqzc4RUSU6JRWK=
NTERA-S-cl-D1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDUSIpyUUN3ME2wMlA2Pzd{IN88US=> NH6zT5RUSU6JRWK=
D-542MG NE[0O2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm4TWM2OD1yLkC1PVU4KM7:TR?= NYDvRpB5W0GQR1XS
KS-1 M3Gye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCybW55UUN3ME2wMlA3PDV6IN88US=> NG\jToNUSU6JRWK=
BL-41 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rYPWlEPTB;MD6wOlk1PyEQvF2= NXHQ[o15W0GQR1XS
LXF-289 NIPWTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHReGZKSzVyPUCuNFcxPjZizszN M2f1fHNCVkeHUh?=
D-247MG MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;0TWM2OD1yLkC3NlA6KM7:TR?= MY\TRW5ITVJ?
MMAC-SF NYf3N4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzNOGtZUUN3ME2wMlA4OjZ6IN88US=> NFXXcW9USU6JRWK=
CP66-MEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHFTWM2OD1yLkC3OUDPxE1? NY\XT4pwW0GQR1XS
LB771-HNC M{XIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKwRoRKSzVyPUCuNFgxOzZizszN NXvvblB4W0GQR1XS
no-10 NIrWfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfHbHhKSzVyPUCuNFg6ODlizszN NU\DOmh4W0GQR1XS
A388 M4\zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDOOYJKSzVyPUCuNFkxPjVizszN NF;xSnRUSU6JRWK=
OPM-2 MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly2TWM2OD1yLkGwOFc1KM7:TR?= MYDTRW5ITVJ?
OVCAR-4 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMUC5N|gh|ryP MmDwV2FPT0WU
HOP-62 M4DiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzwNIdKSzVyPUCuNVA6PDlizszN NYHzSm9zW0GQR1XS
ML-2 NWf3[YlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMUG4NFYh|ryP NIjvXWhUSU6JRWK=
UACC-257 NYPGV3E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nyc2lEPTB;MD6xNVkzPyEQvF2= NUDaS4ZSW0GQR1XS
NEC8 NGroWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW4OG9KSzVyPUCuNVE6QTVizszN M1ruTHNCVkeHUh?=
ONS-76 NUjMOZhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMUK5N|Uh|ryP NY\vdnF[W0GQR1XS
KE-37 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\HWGlEPTB;MD6xN|I4QCEQvF2= MXHTRW5ITVJ?
HT-144 M4H4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW4U3drUUN3ME2wMlE{QDl3IN88US=> MnzFV2FPT0WU
LB2241-RCC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjZPYdKSzVyPUCuNVQzPDdizszN NX[wXZl4W0GQR1XS
TE-5 NFL1WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonCTWM2OD1yLkG0Nlc5KM7:TR?= NYDGWpNNW0GQR1XS
KINGS-1 NUjPeXQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMUS3PUDPxE1? MofTV2FPT0WU
NCI-H69 NX\5fm5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMUWxOFEh|ryP NILVZ4tUSU6JRWK=
CAS-1 NH3wbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV72bWVuUUN3ME2wMlE2PDh{IN88US=> MXHTRW5ITVJ?
D-263MG NWD3T5k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfB[G5KSzVyPUCuNVYxODZizszN MVLTRW5ITVJ?
A253 NIG1Z4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XvVWlEPTB;MD6xOlEzQCEQvF2= M2CwOnNCVkeHUh?=
PF-382 NHfiTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXDe3RKSzVyPUCuNVY4ODZizszN MXPTRW5ITVJ?
CESS NHTLXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj5TWM2OD1yLkG3NFYh|ryP MnryV2FPT0WU
MZ2-MEL MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPuTWM2OD1yLkG3OVU6KM7:TR?= MV\TRW5ITVJ?
HEL MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vyOmlEPTB;MD6xPFUyPyEQvF2= NYWy[pZ[W0GQR1XS
D-392MG NVvYNllKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vDVmlEPTB;MD6xPVEyPSEQvF2= NGfPe4RUSU6JRWK=
SK-LMS-1 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFiyUnFKSzVyPUCuNVk{ODNizszN NYXETWNwW0GQR1XS
GI-ME-N MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXhZoxKSzVyPUCuNVk{ODZizszN MkDqV2FPT0WU
LB831-BLC NHKxVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfieGRPUUN3ME2wMlE6OzRizszN NX;uUZpuW0GQR1XS
DU-4475 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTjTWM2OD1yLkG5OlU5KM7:TR?= M1vSSXNCVkeHUh?=
IST-SL1 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor0TWM2OD1yLkKwNFk1KM7:TR?= M{DVUnNCVkeHUh?=
GAK NXzFS3FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL1TWM2OD1yLkKwOVM1KM7:TR?= MXPTRW5ITVJ?
EW-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPxTXRlUUN3ME2wMlIyODR5IN88US=> M{jROXNCVkeHUh?=
LAMA-84 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMkG4OVEh|ryP NYjYOpFoW0GQR1XS
SK-UT-1 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfnXXVKSzVyPUCuNlIxPDlizszN NIHtdphUSU6JRWK=
VA-ES-BJ NILCdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMkKyOVch|ryP NWXFSpBoW0GQR1XS
ACN MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHZOVFVUUN3ME2wMlIzPjN6IN88US=> NEPIOZFUSU6JRWK=
SK-PN-DW NV7JUZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqwTWM2OD1yLkKzNVkh|ryP NH\yS3ZUSU6JRWK=
HD-MY-Z NVr2T29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPjSYdKSzVyPUCuNlM{ODNizszN NGLFSolUSU6JRWK=
LB373-MEL-D MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LrXGlEPTB;MD6yOFE6QCEQvF2= NEjwWZdUSU6JRWK=
COLO-829 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;JTWM2OD1yLkK0NlU4KM7:TR?= NXO2SZZIW0GQR1XS
ES8 MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXpTWM2OD1yLkK0O|Y{KM7:TR?= MoC5V2FPT0WU
RXF393 M1e0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLwTWM2OD1yLkK1NFE2KM7:TR?= M17TZ3NCVkeHUh?=
TK10 M13VR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW0S5ZOUUN3ME2wMlI2PDN3IN88US=> NYjESpZ{W0GQR1XS
LOUCY NH;5[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPxVVFMUUN3ME2wMlI2PDV4IN88US=> NEjj[pBUSU6JRWK=
MZ7-mel NH;hfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zBdGlEPTB;MD6yOlM4PCEQvF2= NUjVbnZDW0GQR1XS
CP67-MEL M1i2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYryO5psUUN3ME2wMlI3PzNizszN MWPTRW5ITVJ?
C2BBe1 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX0[o1qUUN3ME2wMlI4QTB5IN88US=> NEXk[oRUSU6JRWK=
K052 NWW2W4xKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPnTWM2OD1yLkK4PVkh|ryP M4XvRXNCVkeHUh?=
MOLT-16 M2P4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n6OmlEPTB;MD6yPVUzPCEQvF2= NGSwbFRUSU6JRWK=
KNS-81-FD MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj5VppLUUN3ME2wMlMxOzJ|IN88US=> MXLTRW5ITVJ?
CMK M3LHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLSTWM2OD1yLkOxNVIh|ryP NF3mZphUSU6JRWK=
LAN-6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSxVYpKSzVyPUCuN|E{KM7:TR?= M3vIW3NCVkeHUh?=
KLE MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwM{GzNFYh|ryP MnXxV2FPT0WU
NCCIT M1qwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrTOHRzUUN3ME2wMlMyPzh|IN88US=> NVHQOWw4W0GQR1XS
HH MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLwRZBKSzVyPUCuN|I5QTdizszN MkT2V2FPT0WU
TE-8 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zoR2lEPTB;MD6zOFI4QSEQvF2= NE\6T2FUSU6JRWK=
GDM-1 NGjxN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;UcWlEPTB;MD6zOVExPCEQvF2= NFywU5RUSU6JRWK=
NCI-H747 NVSyVJlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K4OmlEPTB;MD6zO|ExOyEQvF2= MXrTRW5ITVJ?
NCI-H1092 NVvqdmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfpfGRKSzVyPUCuN|g5PDRizszN Mnj1V2FPT0WU
8-MG-BA NG\UNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\hTWM2OD1yLkO5PFM4KM7:TR?= NFXKUmxUSU6JRWK=
NB17 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwNEK5O{DPxE1? MorQV2FPT0WU
LC4-1 M{D3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjIcVJtUUN3ME2wMlQ{PjB5IN88US=> NUPCZ|E4W0GQR1XS
TE-1 NH7PbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLhdGNKSzVyPUCuOFUyOTlizszN MknYV2FPT0WU
KALS-1 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHORlhwUUN3ME2wMlQ3PTh2IN88US=> NHrtXIdUSU6JRWK=
CCRF-CEM M1LoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zFVmlEPTB;MD60O|Y4PCEQvF2= MXLTRW5ITVJ?
OS-RC-2 M3vFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwNEe5O|Ih|ryP M1zxbHNCVkeHUh?=
A704 NIfNSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPOSnpCUUN3ME2wMlQ5Pjl{IN88US=> NXG3UI1NW0GQR1XS
BB49-HNC NF3jN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jafmlEPTB;MD60PVA6PiEQvF2= NFj4e5JUSU6JRWK=
EVSA-T NWTlVWVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\aSlFKSzVyPUCuOFk6OTFizszN M1\WbHNCVkeHUh?=
Mo-T M2fySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDPNWZKSzVyPUCuOVE4PjJizszN MmjlV2FPT0WU
MONO-MAC-6 NGfvcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;GbHpIUUN3ME2wMlU{PjFzIN88US=> MYfTRW5ITVJ?
BB65-RCC Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzoVHRKSzVyPUCuOVY5OTFizszN M37z[HNCVkeHUh?=
NCI-H1882 M37a[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnUTWM2OD1yLkW5NFM3KM7:TR?= MkDLV2FPT0WU
TE-9 NXHxVZZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3KRmFNUUN3ME2wMlYyODN|IN88US=> M1znWXNCVkeHUh?=
NCI-H2126 NIXRb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX1ZXdKSzVyPUCuOlI3PjlizszN MUHTRW5ITVJ?
SF268 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPsTWM2OD1yLk[1OlQyKM7:TR?= MojKV2FPT0WU
SW872 NHLzWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjxOYZKSzVyPUCuOlU4OjlizszN NWHDN|BIW0GQR1XS
LS-513 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33q[GlEPTB;MD62Olc2OSEQvF2= M3fTeXNCVkeHUh?=
NCI-H1355 NGPNSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLNTWM2OD1yLk[4OlE6KM7:TR?= NILZ[XlUSU6JRWK=
BL-70 NFLocFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzuXFdKSzVyPUCuOlk{QDhizszN MnT5V2FPT0WU
NCI-SNU-5 NFjDemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vSU2lEPTB;MD62PVU1PSEQvF2= NHLkTWFUSU6JRWK=
SNU-C2B NH:1dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwN{C3N|kh|ryP NHfvZZRUSU6JRWK=
GB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwN{KxNlQh|ryP MlLFV2FPT0WU
CTB-1 NV32dlh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGxVlVlUUN3ME2wMlc4QTV3IN88US=> M{XtUXNCVkeHUh?=
Becker NFTtcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwN{m2NlEh|ryP NFTxd5ZUSU6JRWK=
KM12 NYfKSXg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwOEW0OlYh|ryP Mn3pV2FPT0WU
ES7 MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwOEm2OUDPxE1? NEL2VWhUSU6JRWK=
COLO-684 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;lTWM2OD1yLkmwOlU5KM7:TR?= MVfTRW5ITVJ?
HCC2998 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfNcIlKSzVyPUCuPVM5PTRizszN Mlr5V2FPT0WU
TE-10 NXKwN4l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL0XZI6UUN3ME2wMlk3PDNizszN M1vGWnNCVkeHUh?=
SF126 M2S4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzoOlRLUUN3ME2wMlk5QTdzIN88US=> MWfTRW5ITVJ?
EKVX NETvNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GybmlEPTB;MT6wN|Q1OiEQvF2= Ml74V2FPT0WU
KARPAS-45 M{jT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSzfXBjUUN3ME2xMlA1ODF4IN88US=> M2P4SXNCVkeHUh?=
KGN MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\kS4dPUUN3ME2xMlA2ODR3IN88US=> NFvHd2dUSU6JRWK=
ES1 NXruOJlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LubmlEPTB;MT6wO|kzOSEQvF2= NUS2PVI3W0GQR1XS
L-540 M3P2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LLeGlEPTB;MT6xNVg{QSEQvF2= MVPTRW5ITVJ?
KURAMOCHI M4TDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPQRZoyUUN3ME2xMlEzOzd2IN88US=> M373cnNCVkeHUh?=
LU-65 M2TRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj5TWM2OD1zLkGyO|U{KM7:TR?= M3nNNXNCVkeHUh?=
MFH-ino NXezWnloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwMUe1NFEh|ryP MVnTRW5ITVJ?
NCI-H23 NGHIbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwMkC0NUDPxE1? M4LpS3NCVkeHUh?=
IA-LM NGrTN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLjV|ZGUUN3ME2xMlI1OTF4IN88US=> NVfmWXNEW0GQR1XS
PSN1 NGS3WYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzs[JBKSzVyPUGuNlcxOTZizszN NHrGb3dUSU6JRWK=
NCI-H719 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnjZ4MxUUN3ME2xMlI4PDFzIN88US=> NEfofFNUSU6JRWK=
SW684 NW\JfIZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO5TWM2OD1zLkK4OlU6KM7:TR?= NWLvVIV3W0GQR1XS
HCE-4 NWXkeopST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7JeW95UUN3ME2xMlMxOjJzIN88US=> M2nhZ3NCVkeHUh?=
EW-16 MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTVdVhoUUN3ME2xMlMyOzR5IN88US=> MlfHV2FPT0WU
NCI-H128 M3jqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYKwUGV4UUN3ME2xMlM2QDF2IN88US=> MWfTRW5ITVJ?
HC-1 M3XF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf6TWM2OD1zLkO4NVch|ryP Mm\NV2FPT0WU
IST-MES1 M{jNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH6V5VzUUN3ME2xMlQxOjB6IN88US=> MWjTRW5ITVJ?
Raji MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[5cGN5UUN3ME2xMlQyQDVizszN MYfTRW5ITVJ?
DMS-114 Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETIbW1KSzVyPUGuOFQ2OzlizszN NYT2eZBrW0GQR1XS
GI-1 NHHwS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHoeGViUUN3ME2xMlQ4OTNzIN88US=> NH\XRVlUSU6JRWK=
NCI-H2081 M3faXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33yUmlEPTB;MT61OVE6PiEQvF2= NUTLN215W0GQR1XS
LC-1F M4jxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fFTGlEPTB;MT61OVE6QCEQvF2= MnrDV2FPT0WU
NCI-H2227 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwNkG1OlEh|ryP MW\TRW5ITVJ?
D-502MG Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwNkeyNVEh|ryP MVXTRW5ITVJ?
NCI-H2141 NUTrdY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwNkezNVch|ryP MWjTRW5ITVJ?
LS-411N NYnKOZQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\iTWM2OD1zLk[5PFA4KM7:TR?= NI[wUZFUSU6JRWK=
SU-DHL-1 M1TSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i0d2lEPTB;MT63NVI5OSEQvF2= NUniSZNVW0GQR1XS
BB30-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uwUmlEPTB;MT63NlY5PSEQvF2= MoO2V2FPT0WU
TE-15 MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nae2lEPTB;MT65NlM4OyEQvF2= NH7GUnFUSU6JRWK=
JVM-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\rXYNbUUN3ME2xMlk{QTB2IN88US=> M4PVOXNCVkeHUh?=
IST-SL2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwMEGyOVIh|ryP MYLTRW5ITVJ?
EW-18 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKyZWpKSzVyPUKuNFI{OzdizszN NG\6VndUSU6JRWK=
DJM-1 NVm0XpIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rsWmlEPTB;Mj6wNlU2OiEQvF2= NFTRTXZUSU6JRWK=
no-11 NVvPWm5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DP[WlEPTB;Mj6wN|ExPCEQvF2= MnTxV2FPT0WU
QIMR-WIL MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDMc4c5UUN3ME2yMlE3PzZ{IN88US=> NXPj[lcyW0GQR1XS
MC-CAR MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjLN4FDUUN3ME2yMlIzQTVizszN MlH3V2FPT0WU
KM-H2 NUjoVGxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XRN2lEPTB;Mj6yPVA1OyEQvF2= MUjTRW5ITVJ?
ECC12 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXLSWhKSzVyPUKuN|c6PCEQvF2= NWLESWk{W0GQR1XS
HCE-T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJwNES4PFMh|ryP MmHUV2FPT0WU
MFM-223 M2jjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\nTWM2OD1{LkWwPFcyKM7:TR?= M2[4Z3NCVkeHUh?=
SW982 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDUeodKSzVyPUKuOVE1QCEQvF2= M{\nO3NCVkeHUh?=
KG-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqzRVl6UUN3ME2yMlg5PzlzIN88US=> M33kXXNCVkeHUh?=
ES4 M2\RbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwME[xNVEh|ryP NEDtNpBUSU6JRWK=
SCC-3 NYTnV49mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHX[HNKSzVyPUOuNVA5PDhizszN NUfYeJUyW0GQR1XS
RH-1 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNwM{i3OFgh|ryP NI\sUoVUSU6JRWK=
NCI-H748 NWW5RoVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXvdZRiUUN3ME2zMlQ1OjZ4IN88US=> MVfTRW5ITVJ?
HCC2218 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nER2lEPTB;Mz60Olk{PyEQvF2= MmHYV2FPT0WU
MEG-01 NW\QTWNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTNwNUm2PEDPxE1? NV3MTVM6W0GQR1XS
NB12 M3zGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNwNUm4PFgh|ryP NEPOfXhUSU6JRWK=
SNB75 NWLPS|g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwNkCxNFMh|ryP MnX3V2FPT0WU
KMS-12-PE MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3T5dxUUN3ME2zMlY4PzJ|IN88US=> MnrMV2FPT0WU
SKM-1 NXfveXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIiyUZNKSzVyPUOuO|E{PzZizszN M4rqTHNCVkeHUh?=
COLO-320-HSR NUHVUVZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTNwN{W2N|Qh|ryP MmXnV2FPT0WU
NKM-1 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETKdotKSzVyPUOuO|c{PzhizszN NWS0bXl5W0GQR1XS
TE-6 M1nRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrLb4tVUUN3ME2zMlk1PTZzIN88US=> MWTTRW5ITVJ?
D-336MG MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TwZmlEPTB;ND6wNVE3PiEQvF2= Ml;NV2FPT0WU
NCI-H1650 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLMXIlKSzVyPUSuNVU4QTdizszN NYjRfId4W0GQR1XS
ES3 NXTXcWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXxd45KSzVyPUSuN|I5OjRizszN NH;De29USU6JRWK=
YT MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTRwM{W0NlQh|ryP NVjEPVJEW0GQR1XS
ES5 NVTkN5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MortTWM2OD12LkSwNlU2KM7:TR?= M4TZ[3NCVkeHUh?=
LB647-SCLC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTRwNU[zNFgh|ryP NWrPTHZtW0GQR1XS
HAL-01 M{niV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O0SWlEPTB;ND61O|A{PCEQvF2= M2jnV3NCVkeHUh?=
LP-1 M{TQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS0VFk{UUN3ME20MlczOzdzIN88US=> MVnTRW5ITVJ?
BC-1 M3PGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr5TWM2OD13LkCwOFQ4KM7:TR?= MUPTRW5ITVJ?
EB-3 NUTXSZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTQT3dKSzVyPUWuNFMxPDFizszN NWL1cnFzW0GQR1XS
GT3TKB M1TaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7XTWM2OD13LkG3OlYzKM7:TR?= M2fKb3NCVkeHUh?=
NCI-H209 M2W4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljlTWM2OD13LkG5N|UzKM7:TR?= MXrTRW5ITVJ?
BT-474 NHLYXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKxeFZKSzVyPUWuNlMyODJizszN MmHRV2FPT0WU
RKO MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTVwMkO0NlIh|ryP MX7TRW5ITVJ?
SIMA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[1TWM2OD13LkOwO|Y2KM7:TR?= M176W3NCVkeHUh?=
RL NFfNVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPSTWM2OD13LkO3OVQyKM7:TR?= M4XDXHNCVkeHUh?=
GCIY NW\rO4Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzhTWM2OD13LkS3NlM3KM7:TR?= M12wbXNCVkeHUh?=
Calu-6 NVnIWI9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LLdmlEPTB;NT62NlIh|ryP M{DMeHNCVkeHUh?=
ALL-PO M{DZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTVwNkO3PVUh|ryP MVvTRW5ITVJ?
ARH-77 M2nubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLRUINKSzVyPUWuOlcxQDdizszN MkDhV2FPT0WU
A4-Fuk NFfOS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXVR3lKSzVyPU[uNFgyOThizszN M4fWS3NCVkeHUh?=
NCI-H1581 NEC5VWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P5TGlEPTB;Nj6yN|g1QSEQvF2= NYXvTYpTW0GQR1XS
HUTU-80 NHfl[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTZwM{[4PVch|ryP MVvTRW5ITVJ?
TGW MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfDTWQ5UUN3ME22MlQ2PTl|IN88US=> NH3PZlRUSU6JRWK=
SK-N-FI MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmyboNKSzVyPU[uOFU5PTRizszN NYq5VnV6W0GQR1XS
U-266 NUmwTHJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGewWJVKSzVyPU[uOVE6OjZizszN MnLsV2FPT0WU
EM-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTJNY81UUN3ME22MlY4ODl7IN88US=> NV3ScotKW0GQR1XS
NMC-G1 M2DqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXnVWg3UUN3ME22MlcyQDl3IN88US=> MknjV2FPT0WU
KASUMI-1 NILSdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKzTlA3UUN3ME22Mlg1Pzh5IN88US=> Mn[4V2FPT0WU
NALM-6 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrJTWM2OD14Lki2O|U1KM7:TR?= NIf3fm9USU6JRWK=
OCI-AML2 M{LWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[4T|RKSzVyPUeuNFA{OjZizszN M4DyNXNCVkeHUh?=
SHP-77 NWryZmhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn0NpV5UUN3ME23MlIzPDNizszN M4Htc3NCVkeHUh?=
NOMO-1 M4rjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnBVVhKSzVyPUeuNlQzPTRizszN MXnTRW5ITVJ?
SK-N-DZ M3nUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTdwN{GwPFkh|ryP M{m1T3NCVkeHUh?=
LB1047-RCC NWPPNZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTdwN{KyN|Eh|ryP MUnTRW5ITVJ?
MZ1-PC NWPYXlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrofFdmUUN3ME23Mlg3PTV6IN88US=> MXXTRW5ITVJ?
NB10 NEDyVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PrSWlEPTB;Nz65PVU2PiEQvF2= M{D4Z3NCVkeHUh?=
RL95-2 NEfzTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHq[GNKSzVyPUiuNVA5PDJizszN MYXTRW5ITVJ?
OMC-1 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LJW2lEPTB;OD61NlE6OSEQvF2= NVP5N|k{W0GQR1XS
D-283MED NXLuO4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\qTWM2OD16LkmxO|E6KM7:TR?= MW\TRW5ITVJ?
MC116 NE\L[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK4fmhKSzVyPUiuPVc6PCEQvF2= M1qyO3NCVkeHUh?=
SJSA-1 NWP1[Yo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f5SGlEPTB;OT6wPVA6OSEQvF2= M2XOdnNCVkeHUh?=
JiyoyeP-2003 NVXwTYZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K3bGlEPTB;OT6yPVMyPyEQvF2= NW\y[2I5W0GQR1XS
IST-MEL1 NE\IOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DjUmlEPTB;OT63OFE6QCEQvF2= NIDObmhUSU6JRWK=
CTV-1 NYTzd|MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr4TWM2OD1zMD6wPVc6KM7:TR?= NEW2doJUSU6JRWK=
NH-12 NVPFd4JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrHd5lMUUN3ME2xNE4zPDN|IN88US=> MYnTRW5ITVJ?
CA46 NFnESmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT2e5BKSzVyPUGwMlM3OSEQvF2= MUPTRW5ITVJ?
NCI-SNU-1 MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD2TWM2OD1zMD60PVY6KM7:TR?= MnW5V2FPT0WU
SCLC-21H NGq0W21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\aTWM2OD1zMD62OVk3KM7:TR?= NF\5WpBUSU6JRWK=
EC-GI-10 M{XXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfiXlV5UUN3ME2xNE44ODNzIN88US=> MX;TRW5ITVJ?
SR NV7kUINPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvHPVl2UUN3ME2xNU4xOTh3IN88US=> NEfmUZNUSU6JRWK=
NCI-H1648 NVjabWpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLrOGVWUUN3ME2xNU4xQTZ3IN88US=> NY[3OmJvW0GQR1XS
TGBC1TKB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP6O4g6UUN3ME2xNU41OTB{IN88US=> M3r3U3NCVkeHUh?=
EW-11 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzrfFVwUUN3ME2xNU42OTh4IN88US=> MXvTRW5ITVJ?
SK-MM-2 NH[5R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnRZoxnUUN3ME2xNU45ODZzIN88US=> MmXZV2FPT0WU
NCI-H524 NXzkfXlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjPTWM2OD1zMT65PFIzKM7:TR?= NEnvb29USU6JRWK=
NOS-1 NYL0NnRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;BfFZKSzVyPUGyMlA{PDVizszN M3z5c3NCVkeHUh?=
AM-38 NVLtNGN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz5TWM2OD1zMj61OlM{KM7:TR?= NV3oXWZnW0GQR1XS
A498 NHHQUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXJVGZtUUN3ME2xNk44ODZ7IN88US=> NInoTnFUSU6JRWK=
KARPAS-422 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu5NGtCUUN3ME2xNk44PDl4IN88US=> NWK1UndCW0GQR1XS
LU-139 NIH1WIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC0UJFjUUN3ME2xNk46ODJ4IN88US=> MmfPV2FPT0WU
COR-L88 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy4epR[UUN3ME2xNk46Ozh{IN88US=> NIPsV5pUSU6JRWK=
K5 NUfUb4VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO2TWM2OD1zMj65OFYzKM7:TR?= NVv0UWxRW0GQR1XS
NB13 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIeyWGJKSzVyPUGyMlk4QDNizszN NYCwcHNNW0GQR1XS
MRK-nu-1 NHvKbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzITWM2OD1zMz6xPVUh|ryP NFnNRYJUSU6JRWK=
MHH-NB-11 MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz6V|VKSzVyPUGzMlI6ODJizszN M1u5WXNCVkeHUh?=
KU812 M1e1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF|Lk[xNlQh|ryP NHnhc4tUSU6JRWK=
TE-12 M{\rNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnsU4d1UUN3ME2xN{43QTl2IN88US=> NGj3T4VUSU6JRWK=
NCI-N87 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkToTWM2OD1zMz63N|Yh|ryP MoTBV2FPT0WU
EB2 M2T6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;oXmxKSzVyPUGzMlg2ODVizszN NGKwVGxUSU6JRWK=
DB NYPxPHI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PFXmlEPTB;MUOuPVg5PSEQvF2= MVXTRW5ITVJ?
697 NY\y[XV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S5cGlEPTB;MUSuOFUyOSEQvF2= M4T1WXNCVkeHUh?=
MSTO-211H M1nQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq2TWM2OD1zND63OFQ5KM7:TR?= NFvFXoZUSU6JRWK=
JVM-2 NF:5[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnEeIVWUUN3ME2xOE44PzN3IN88US=> MVPTRW5ITVJ?
COLO-824 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF2Lke5PVQh|ryP MYHTRW5ITVJ?
BC-3 NWHkUJkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXESXVKSzVyPUG1MlM6QCEQvF2= NVnX[VZsW0GQR1XS
BOKU NHXi[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LWZWlEPTB;MUWuPVYxQCEQvF2= M1rHUXNCVkeHUh?=
GOTO MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEezRYNKSzVyPUG2Mlk3OTdizszN NVP6VYhUW0GQR1XS
HCC2157 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF5LkS3OVUh|ryP NV\jUYQ6W0GQR1XS
LS-1034 NX\QWFh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfrTWM2OD1zNz62PFE5KM7:TR?= M1;YbHNCVkeHUh?=
CAL-148 M13rUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLOTWM2OD1zNz65O|k3KM7:TR?= MUTTRW5ITVJ?
MOLT-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q0NWlEPTB;MUiuPFIxQCEQvF2= NWjrTpJPW0GQR1XS
Daudi NUDz[ZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF6LkmyN|Eh|ryP NFHYPZFUSU6JRWK=
J-RT3-T3-5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF7LkSwOlYh|ryP MojPV2FPT0WU
KMOE-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzoeWlMUUN3ME2xPU43PDh{IN88US=> MUnTRW5ITVJ?
HL-60 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\0XWJvUUN3ME2yNE4yQTZ3IN88US=> NF[zSlNUSU6JRWK=
P31-FUJ M4Dpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHnTWM2OD1{MD60O|U{KM7:TR?= NGDv[WhUSU6JRWK=
IM-9 M{HBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnNTWM2OD1{MD62NlI1KM7:TR?= M17QUXNCVkeHUh?=
HDLM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrTOnduUUN3ME2yNE45QDJzIN88US=> NXfac4xCW0GQR1XS
NCI-H1304 MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vmZWlEPTB;MkGuNFMyOSEQvF2= M1fOfHNCVkeHUh?=
NCI-H345 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL2WGZKSzVyPUKxMlA3PDNizszN NFy4OGhUSU6JRWK=
RPMI-6666 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonKTWM2OD1{MT6zOlAzKM7:TR?= M4n3cXNCVkeHUh?=
GR-ST NWGwb|RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJzLkSxO{DPxE1? MX;TRW5ITVJ?
CHP-126 NF3wV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLPSYplUUN3ME2yNU43OThzIN88US=> NXj5S|FzW0GQR1XS
EHEB M1njcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr1UWxKSzVyPUKxMlY4OzFizszN Ml\pV2FPT0WU
CPC-N NInjOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXftZm5RUUN3ME2yOE4xOjBzIN88US=> NWf1PHA1W0GQR1XS
NB1 M3fUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TNUmlEPTB;MkSuOlk{QSEQvF2= MXvTRW5ITVJ?
LS-123 M3zZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjoTWM2OD1{ND65NFEzKM7:TR?= NUTYfWhoW0GQR1XS
ST486 M134cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rSZmlEPTB;MkWuNVEyOyEQvF2= MWPTRW5ITVJ?
NCI-H1963 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHrVWNKSzVyPUK2MlA3OjNizszN M2nlcnNCVkeHUh?=
U-87-MG NFXod5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXsUoJKSzVyPUK2Mlc3PDRizszN NWDhOFB{W0GQR1XS
COR-L279 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XMV2lEPTB;Mk[uO|kzOiEQvF2= NWn0OXh2W0GQR1XS
LU-165 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fOeWlEPTB;MkiuNFg3OSEQvF2= NYizW444W0GQR1XS
COLO-800 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;EdVFKSzVyPUK4MlI6PTZizszN M3TuNnNCVkeHUh?=
ETK-1 NV7WXoF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j4fWlEPTB;MkiuN|Q1PiEQvF2= M2[wTXNCVkeHUh?=
LNCaP-Clone-FGC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ7LkmyPFEh|ryP NGXGOIlUSU6JRWK=
SIG-M5 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHmVIQ{UUN3ME2zNE44QTV{IN88US=> NXrQWJZTW0GQR1XS
NB6 NV3oPI5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XkemlEPTB;M{CuPVUxOyEQvF2= NIPWR2NUSU6JRWK=
NCI-H2107 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPGOI1xUUN3ME2zNU4zOzN6IN88US=> MVXTRW5ITVJ?
SNU-C1 NGH1XohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNzLkOxNlYh|ryP Mn\sV2FPT0WU
JAR NETvdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfIZ5pKSzVyPUOxMlM4QTlizszN Ml\hV2FPT0WU
L-363 MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTN{LkKxOFQh|ryP MnLSV2FPT0WU
EW-24 MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LLRWlEPTB;M{KuN|Q4PCEQvF2= NVexOWNxW0GQR1XS
NB69 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PlU2lEPTB;M{OuOlQ2PCEQvF2= NEDPfnJUSU6JRWK=
EW-13 NXGwOZR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fJTmlEPTB;M{OuPFk3QSEQvF2= MYLTRW5ITVJ?
Ramos-2G6-4C10 NVLnW3VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN2LkK5PVMh|ryP NWHye3N4W0GQR1XS
TE-11 M2HRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jsPWlEPTB;M{SuOFgzOiEQvF2= Ml;yV2FPT0WU
L-428 NGm0NJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELleHRKSzVyPUO0Mlc2OzZizszN NVT3UndPW0GQR1XS
KP-N-YN MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7qcWpMUUN3ME2zOE46ODV5IN88US=> MoS2V2FPT0WU
CGTH-W-1 NXn0fY9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rhVGlEPTB;M{[uPVA1QCEQvF2= MU\TRW5ITVJ?
K-562 NVnBcVZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTN5LkC4OlQh|ryP Mk\ZV2FPT0WU
NCI-H1299 NETNRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHiWlhKSzVyPUO4MlE3ODNizszN NGjOUIpUSU6JRWK=
RCC10RGB NXLWfZIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LUb2lEPTB;M{iuNlA5OyEQvF2= NHv5ZZdUSU6JRWK=
NCI-SNU-16 NH74dpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L6ZmlEPTB;M{iuOVY2OyEQvF2= Mnj0V2FPT0WU
LC-2-ad M2\tOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN7LkSzN|ch|ryP Mkm5V2FPT0WU
MHH-PREB-1 NXO1W2F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PtbWlEPTB;M{muO|M5QCEQvF2= Mn7pV2FPT0WU
NCI-H64 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRyLkC5OFgh|ryP MkjPV2FPT0WU
LB996-RCC NWPYZYRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7mXYFNUUN3ME20NE45PzF4IN88US=> NUT3[m5ZW0GQR1XS
DEL NIfuSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf3Nod1UUN3ME20NU41PDB3IN88US=> M1\pNnNCVkeHUh?=
MLMA NVvKV2gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK4TWM2OD12MT63OVk2KM7:TR?= NHjSdWtUSU6JRWK=
SBC-1 M2fQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfPdlRkUUN3ME20Nk4yQDB4IN88US=> NH3ybpJUSU6JRWK=
MPP-89 NITjU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u3[GlEPTB;NEKuOVg4PSEQvF2= M3jrUXNCVkeHUh?=
MV-4-11 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rYUmlEPTB;NEKuPVA3PyEQvF2= M{Pne3NCVkeHUh?=
EoL-1- NIHnSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG3TWM2OD12ND6xOVY5KM7:TR?= Mme2V2FPT0WU
CW-2 NYTJSFVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHt[FJ1UUN3ME20OE45OzR{IN88US=> NYe2TJJnW0GQR1XS
HT NIOyWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR3LkewNFch|ryP M4X3R3NCVkeHUh?=
SW954 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUezXWlJUUN3ME20O{41OTJ6IN88US=> MX3TRW5ITVJ?
A3-KAW NXX4U5NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR7LkiwOlEh|ryP MkHvV2FPT0WU
TC-YIK NWG0SXFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPhPIhKSzVyPUWwMlA{PjNizszN MYHTRW5ITVJ?
SW962 NWn4bod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTV2LkizOVch|ryP M1nqd3NCVkeHUh?=
KP-N-RT-BM-1 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW1TWM2OD13Nj62OlM5KM7:TR?= MlPIV2FPT0WU
NCI-H1395 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LvfWlEPTB;NUiuPFE4OiEQvF2= NHLYTG5USU6JRWK=
RPMI-8402 NUTy[IU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLaTWM2OD13OD65OVI3KM7:TR?= NH3QfXVUSU6JRWK=
SCH MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG4TWM2OD14MD65OlM5KM7:TR?= M2qzfXNCVkeHUh?=
NCI-H2196 M{DhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHSTWM2OD14MT6yN|Eh|ryP MXTTRW5ITVJ?
LOXIMVI MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\FTWM2OD14MT64NlY3KM7:TR?= NIOyU5NUSU6JRWK=
TGBC24TKB NWDa[JlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\HOGlEPTB;NkKuNVQ6OSEQvF2= M3XCRXNCVkeHUh?=
SK-MEL-2 M17I[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HJR2lEPTB;NkOuPVg6OiEQvF2= NFnHVXpUSU6JRWK=
U-698-M MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M325TGlEPTB;NkiuOVY5PyEQvF2= MU\TRW5ITVJ?
NCI-H1522 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\Le2lEPTB;NkmuNFA1PyEQvF2= MmTZV2FPT0WU
UACC-812 NEDGflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXT[WRKSzVyPU[5MlUzODlizszN M2\DVHNCVkeHUh?=
MHH-CALL-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofwTWM2OD15MD6wOkDPxE1? Mli2V2FPT0WU
NB5 NWj3b486T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTdyLkO0Olgh|ryP NI\qbJNUSU6JRWK=
KARPAS-299 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXYbI9KSzVyPUewMlQ1PDdizszN NEf0c2ZUSU6JRWK=
NCI-H1694 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX5TIxsUUN3ME23NU4xOzJizszN M1LGR3NCVkeHUh?=
NCI-H82 NESzem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTdzLkm1NFch|ryP NXPDU4FDW0GQR1XS
SCC-15 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LuUGlEPTB;N{KuN|Qh|ryP MkX3V2FPT0WU
NCI-H1436 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDjelhKSzVyPUeyMlc1PTZizszN MYLTRW5ITVJ?
ATN-1 NYLHU292T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoSxTWM2OD15ND61NFUh|ryP M1vjc3NCVkeHUh?=
RPMI-8866 NYDxWJQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\BTWM2OD15ND63OVA6KM7:TR?= M4GwU3NCVkeHUh?=
HCC1599 NFPqWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTd2Lki3N|Ih|ryP MV7TRW5ITVJ?
NCI-H1155 Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTd2LkmzOlch|ryP NEHVSplUSU6JRWK=
DOHH-2 NFLxfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTd2Lkm1NVQh|ryP NFTCbWtUSU6JRWK=
SK-NEP-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrzbVl5UUN3ME23OU4xPzV2IN88US=> NF7GWnFUSU6JRWK=
HCC1187 MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLUUY1GUUN3ME23O{43OTJ{IN88US=> NXTxPY93W0GQR1XS
NCI-H322M NIPaWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17GPWlEPTB;N{iuN|cxQSEQvF2= MVnTRW5ITVJ?
NCI-H526 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\nTWM2OD15OD61PFc4KM7:TR?= NV7vcot4W0GQR1XS
NCI-H2171 NHT0doRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTd7LkSxN|Yh|ryP NWe1PXJKW0GQR1XS
COLO-668 M4PFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPaOpVIUUN3ME24NU42QDh2IN88US=> M1L1ZnNCVkeHUh?=
RS4-11 NUX6WlhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDWfHZKSzVyPUiyMlI2ODVizszN Mo\0V2FPT0WU
NCI-H716 M3HHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHHZldKSzVyPUiyMlkxPzVizszN NIfXVZFUSU6JRWK=
LU-134-A M{Tqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTh|LkGzOVEh|ryP M{\DWXNCVkeHUh?=
RPMI-8226 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDCfGJ6UUN3ME24OE4zOTB5IN88US=> NFfaO5pUSU6JRWK=
KY821 NXL4XohnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nZS2lEPTB;OUGuOlU2OSEQvF2= M322OXNCVkeHUh?=
ECC4 NXT3ZXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q1emlEPTB;OUOuPFI3QSEQvF2= NEjaOG5USU6JRWK=
EW-3 NWjRNolCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPv[phKSzVyPUm0MlkxQDFizszN MXrTRW5ITVJ?
NB7 NVPFfWVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jyUGlEPTB;OUWuO|c5PiEQvF2= M4\ZdnNCVkeHUh?=
NCI-H720 NELBdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;McZBnUUN3ME25PE41ODZzIN88US=> M2XCbXNCVkeHUh?=
NCI-H446 NVfLXWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTT[oNEUUN3ME25PU44PTh6IN88US=> NV3DdVBoW0GQR1XS
NCI-H889 NUTJcZZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjyTWM2OD1zMESuNlQzKM7:TR?= M1KyTHNCVkeHUh?=
EW-22 NVzQXmRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[0dXZoUUN3ME2xNFYvOTlizszN NX:1R|E{W0GQR1XS
BV-173 M2K1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj6UpZKSzVyPUGwPE44OjhizszN M2GyN3NCVkeHUh?=
WSU-NHL NYjOVIJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;MZnFKSzVyPUGwPU43PzFizszN MYrTRW5ITVJ?
MN-60 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiwNm1KSzVyPUGwPU43QSEQvF2= NGLxeotUSU6JRWK=
DG-75 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFzMz6zOVIh|ryP MWjTRW5ITVJ?
DMS-79 NFjqWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfMTWM2OD1zMUeuN|gzKM7:TR?= MkK0V2FPT0WU
SK-MEL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvMXVBKSzVyPUGxPE4xODlizszN M{DYVXNCVkeHUh?=
DMS-153 NYPGZolnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTWbG9KSzVyPUGyNU44PDVizszN M17Le3NCVkeHUh?=
NCI-H510A MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnflTWM2OD1zMkeuN|Ih|ryP MkTpV2FPT0WU
BE-13 NYTaclRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HjSGlEPTB;MUO0MlA1PCEQvF2= NHjXeZdUSU6JRWK=
KP-N-YS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HCRmlEPTB;MUO5Mlc{PiEQvF2= NHjKSWFUSU6JRWK=
SUP-T1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Ho[mlEPTB;MUSzMlcxQCEQvF2= MmnaV2FPT0WU
EW-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf0O2RKSzVyPUG0OE43QTlizszN MWXTRW5ITVJ?
NB14 NUTCfo5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojkTWM2OD1zNEeuNFgzKM7:TR?= MojVV2FPT0WU
MDA-MB-134-VI M{fvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF2OD6yOlgh|ryP NUHvXnlTW0GQR1XS
NCI-H1770 NXWzeXBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGezUJRKSzVyPUG1Ok4zPzlizszN Ml7PV2FPT0WU
TUR NGrwWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL1[JNpUUN3ME2xOlcvQDdizszN MY\TRW5ITVJ?
NCI-H1417 NVj2SmNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnUTWM2OD1zOECuN|MyKM7:TR?= M4rLRXNCVkeHUh?=
IMR-5 NViwfZZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC4OmVKSzVyPUG4NU42PzFizszN NV;LRlZoW0GQR1XS
NCI-H226 NUW3TFVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkewTWM2OD1zOEiuPFY3KM7:TR?= MWXTRW5ITVJ?
NCI-H187 M4faTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L4W2lEPTB;MUmwMlA3PCEQvF2= MoTIV2FPT0WU
SF539 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3viWmlEPTB;MUmyMlczQCEQvF2= NGj0elNUSU6JRWK=
TALL-1 NH;qblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTIeIVKSzVyPUG5PE4{ODRizszN NUm3XI9wW0GQR1XS
TE-441-T NF3xfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH3V4tKSzVyPUG5PU44OzlizszN MUDTRW5ITVJ?
REH MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DjN2lEPTB;MkO2MlYzPiEQvF2= NFrkZ45USU6JRWK=
MS-1 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzxUJdKSzVyPUKzPU4yOjFizszN NFjFZ49USU6JRWK=
THP-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ4ND63N|gh|ryP NIH4e3pUSU6JRWK=
NCI-H1838 NGT1WY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLmbpFCUUN3ME2yO|EvPDV4IN88US=> M13JWXNCVkeHUh?=
P30-OHK M3;3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M325VWlEPTB;MkizMlg1PyEQvF2= NFK3NWdUSU6JRWK=
C8166 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ibWlEPTB;M{S1MlM{QCEQvF2= MYPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
Bcr-Abl; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Ac-histone H3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-caspase3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-PARP; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

ASCL1; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

CgA; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

Nrf2; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

HO-1; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

26722260 19765735 23604711
Immunofluorescence
C2GnT-M / NMIIA; 

PubMed: 22525330     


Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E).

AGS3 / Vimentin; 

PubMed: 20065032     


COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections.

Bak; 

PubMed: 20557369     


Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.

22525330 20065032 20557369
Growth inhibition assay
Apoptosis assay; 

PubMed: 20557369     


LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells)

Cell viability; 

PubMed: 26137056     


The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner.

cell proliferation ; 

PubMed: 19765735     


MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)

20557369 26137056 19765735
ELISA
IL-8; 

PubMed: 11160671     


ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. 

IL-1beta; 

PubMed: 22606244     


LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.

11160671 22606244
In vivo

Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

- Collapse

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

- Collapse
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)CC(NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1)C=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID